Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Laminin alpha-3 Monoclonal Antibody (546215), Invitrogen™
Mouse Monoclonal Antibody
Supplier: Thermo Scientific MA524246
Description
In direct ELISAs, no cross reactivity with recombinant human Laminin alpha 1, beta 1, gamma 2, or recombinant mouse Laminin alpha 4 is observed. Reconstitute at 0.5 mg/mL in sterile PBS.
Laminin alpha-3 Monoclonal antibody specifically detects Laminin alpha-3 in Human samples. It is validated for Flow Cytometry, Immunocytochemistry, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot.Specifications
Laminin alpha-3 | |
Monoclonal | |
0.5 mg/mL | |
PBS with 5% trehalose and No Preservative | |
Q16787 | |
LAMA3 | |
CHO-derived recombinant human Laminin alpha 3/Laminin-5 (aa 21-1713) | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG1 |
Flow Cytometry, Immunocytochemistry, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot | |
546215 | |
Unconjugated | |
LAMA3 | |
[a]3B; BM600; BM600 150kD subunit; E170; Epiligrin; Epiligrin 170 kDa subunit; epiligrin alpha 3 subunit; epiligrin subunit alpha; kalinin 165kD subunit; kalinin subunit alpha; LAM3, alpha-3 subunit; Lama3; Lama3B; laminin 5 alpha 3; laminin 5, alpha-3 subunit; laminin A3; laminin subunit alpha 3; laminin subunit alpha-3; laminin, alpha 3; laminin, alpha 3 (nicein (150kD), kalinin (165kD), BM600 (150kD), epilegrin); Laminin-5; laminin-5 alpha 3 chain; laminin-5 subunit alpha; Laminin-6 subunit alpha; laminin-7 subunit alpha; LAMNA; LOCS; nicein 150kD subunit; nicein subunit alpha; nicein, 150kDa | |
Mouse | |
Protein A/G | |
RUO | |
3909 | |
-20° C, Avoid Freeze/Thaw Cycles | |
Lyophilized |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction